title: Periorbital changes associated with topical bimatoprost.
abstract: OBJECTIVE
  To describe periorbital changes induced by chronic topical therapy with daily bimatoprost 0.03% (Lumigan, Allergan Inc., Irvine, CA, U.S.A.).
  
  
  METHODS
  A clinical investigation of 5 nonconsecutive patients with unilateral glaucoma treated daily with topical bimatoprost 0.03% for up to 4 years prior to presentation.
  
  
  RESULTS
  In eyes treated with bimatoprost 0.03% the authors noted periorbital fat atrophy, deepening of the upper eyelid sulcus, relative enophthalmos, loss of the lower eyelid fullness, and involution of dermatochalasis compared with the fellow untreated eye. By inspecting old photographs the authors confirmed that these unilateral changes were not present prior to starting bimatoprost. In addition, these changes were partially reversible after discontinuation of the medication, whenever that was possible. In 2 cases imaging studies confirmed the clinical impression that these findings were not related to primary orbital pathology.
  
  
  CONCLUSIONS
  Physicians and patients should be aware of the potential of bimatoprost 0.03% to produce periorbital changes.
authors.affiliation: Department of Ophthalmology, Glaucoma Consultation Service, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts 02114, USA.
authors.forename: Theodoros
authors.initials: T
authors.lastname: Filippopoulos
authors.forename: Jayter S
authors.initials: JS
authors.lastname: Paula
authors.forename: Nurhan
authors.initials: N
authors.lastname: Torun
authors.forename: Mark P
authors.initials: MP
authors.lastname: Hatton
authors.forename: Louis R
authors.initials: LR
authors.lastname: Pasquale
authors.forename: Cynthia L
authors.initials: CL
authors.lastname: Grosskreutz
mesh_terms: D000273:Adipose Tissue / Q000187:drug effects*; D000287:Administration, Topical; D000368:Aged; D000577:Amides / Q000008:administration & dosage / Q000009:adverse effects*; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001284:Atrophy / Q000139:chemically induced; D000069580:Bimatoprost; D003008:Cloprostenol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D003483:Cutis Laxa / Q000139:chemically induced* / Q000175:diagnosis; D015841:Enophthalmos / Q000139:chemically induced / Q000175:diagnosis; D005141:Eyelid Diseases / Q000139:chemically induced* / Q000175:diagnosis; D005260:Female; D005901:Glaucoma / Q000188:drug therapy; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000008:administration & dosage / Q000009:adverse effects; D014057:Tomography, X-Ray Computed
chemical_list: D000577:Amides; D000959:Antihypertensive Agents; D009883:Ophthalmic Solutions; D003008:Cloprostenol; D000069580:Bimatoprost